Efficacy of buparlisib in treating breast cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14656566.2017.1410139PMID 29169282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

  2017cited by this paper
• Game of TOR — The Target of Rapamycin Rules Four Kingdoms

  2017cited by this paper
• Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

  2017influential reference
• Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.

  2016cited by this paper
• A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

  2016cited by this paper
• Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

  2015cited by this paper
• A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

  2015influential reference
• Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2014influential reference
• Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

  2014cited by this paper
• 445ODOSE-ESCALATION STUDY OF SONIDEGIB (LDE225) PLUS BUPARLISIB (BKM120) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS.

  2014cited by this paper
• Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

  2014cited by this paper
• Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

  2014influential reference
• Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

  2014cited by this paper
• Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

  2014cited by this paper
• Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

  2014cited by this paper
• Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

  2014cited by this paper
• Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study.

  2013cited by this paper
• Phosphoinositide 3‐kinase and INPP4B in human breast cancer

  2013cited by this paper
• Development of PI3K inhibitors: lessons learned from early clinical trials

  2013cited by this paper
• Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE

  2013cited by this paper
• Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

  2013cited by this paper
• Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor

  2012cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

  2012cited by this paper
• Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

  2012cited by this paper
• A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

  2012cited by this paper
• Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

  2012influential reference
• Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.

  2011cited by this paper
• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

  2011cited by this paper
• Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

  2011influential reference
• Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

  2011cited by this paper
• AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

  2011cited by this paper
• Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.

  2011influential reference
• Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

  2010cited by this paper
• PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality

  2010influential reference
• Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

  2010cited by this paper
• Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

  2009influential reference
• Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase.

  2009cited by this paper
• Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

  2009cited by this paper
• AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

  2009cited by this paper
• Targeting PI3K signalling in cancer: opportunities, challenges and limitations

  2009influential reference
• PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

  2009cited by this paper
• A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

  2008influential reference
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

  2008influential reference
• Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation

  2006cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia.

  2006cited by this paper
• Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer

  2001cited by this paper
• Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

  2001cited by this paper
• Cancer statistics

  1989cited by this paper
• Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology and Biochemistr and Biochemistr and Biochemistr and Biochemistr and Biochemistryyyyy Phosphatidylinositide Dependent Kinase Deficiency Increases Anxiety and Decreases GABA and Serotonin Abundance in t

  year unknowncited by this paper

• Research update on the anticancer effects of buparlisib.

  2021cites this paper
• Novel 3-fluoro-4-morpholinoaniline derivatives: Synthesis and assessment of anti-cancer activity in breast cancer cells

  2021cites this paper
• Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway.

  2020cites this paper
• B cell modulation strategies in the improvement of transplantation outcomes.

  2020cites this paper
• Anticancer effect of pan‐PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance

  2019cites this paper
• Benefits versus risk profile of buparlisib for the treatment of breast cancer

  2019cites this paper
• Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).

  2019cites this paper
• Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3.

  2018cites this paper